AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Mobix Labs, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Disc Medicine, Inc. (IRON) â€� Form 4 insider transaction filed 07/11/2025

Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.

  • Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
  • Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
  • Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.

The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.

Disc Medicine, Inc. (IRON) � Transazione interna Form 4 presentata il 11/07/2025

Il CEO e Direttore John D. Quisel ha segnalato l'esercizio di un'opzione e due vendite sul mercato aperto eseguite il 09/07/2025 nell'ambito di un piano di trading Rule 10b5-1 adottato il 13/02/2025.

  • Esercizio opzione (Codice M): 34.800 azioni esercitate a 9,86 $ per azione, derivanti da un premio opzione del 1 settembre 2021 che si matura in 48 rate mensili uguali.
  • Vendite (Codice S): L'intero lotto di 34.800 azioni esercitate è stato venduto lo stesso giorno in due tranche: 31.207 azioni a un prezzo medio ponderato di 55,2312 $ (intervallo 55,00-55,99 $) e 3.593 azioni a un prezzo medio ponderato di 56,1995 $ (intervallo 56,00-56,33 $).
  • Posizione netta azionaria: La proprietà effettiva è salita brevemente a 196.628 azioni dopo l'esercizio, per poi scendere a 161.828 azioni dopo le vendite, senza variazioni nette rispetto alla quota precedente alla transazione.

La segnalazione indica una gestione di liquidità di routine da parte del CEO; non vi sono impatti sui flussi di cassa aziendali. Poiché le transazioni erano pianificate in anticipo e il livello complessivo di proprietà è rimasto invariato, l'impatto sul mercato è probabilmente limitato.

Disc Medicine, Inc. (IRON) � Transacción interna Formulario 4 presentada el 11/07/2025

El Director Ejecutivo y Director John D. Quisel reportó el ejercicio de una opción y dos ventas en mercado abierto realizadas el 09/07/2025 bajo un plan de negociación Rule 10b5-1 adoptado el 13/02/2025.

  • Ejercicio de opción (Código M): 34.800 acciones ejercidas a $9.86 por acción, provenientes de una concesión de opción del 1 de septiembre de 2021 que se adquiere en 48 cuotas mensuales iguales.
  • Ventas (Código S): La totalidad de las 34.800 acciones ejercidas se vendieron el mismo día en dos tramos: 31.207 acciones a un precio promedio ponderado de $55.2312 (rango $55.00-$55.99) y 3.593 acciones a un precio promedio ponderado de $56.1995 (rango $56.00-$56.33).
  • Posición neta de acciones: La propiedad beneficiaria aumentó brevemente a 196.628 acciones tras el ejercicio, pero volvió a bajar a 161.828 acciones después de las ventas, sin cambios netos respecto a la participación previa a la transacción.

La presentación indica una gestión rutinaria de liquidez por parte del CEO; no se afectan los flujos de caja de la empresa. Dado que las transacciones fueron planificadas con anticipación y el nivel general de propiedad no cambió, el impacto en el mercado probablemente sea limitado.

Disc Medicine, Inc. (IRON) â€� 2025ë…� 7ì›� 11ì� 제출ë� Form 4 ë‚´ë¶€ìž� 거래 ë³´ê³ 

최고경ì˜ìž� ê²� ì´ì‚¬ John D. QuiselëŠ� 2025ë…� 7ì›� 9ì¼ì— 2025ë…� 2ì›� 13ì� 채íƒë� Rule 10b5-1 거래 계íšì—� ë”°ë¼ ì˜µì…˜ 행사 ë°� ë‘� ê±´ì˜ ê³µê°œì‹œìž¥ 매ë„ë¥� 보고했습니다.

  • 옵션 행사 (코드 M): 2021ë…� 9ì›� 1ì� ë¶€ì—¬ëœ ì˜µì…˜ì—서 매월 48íš� 균등 ë¶„í• ë¡� 권리가 부여ë˜ëŠ� 34,800주를 주당 $9.86ì—� 행사í•�.
  • ë§¤ë„ (코드 S): 행사í•� 34,800ì£� 전량ì� ë‹¹ì¼ ë‘� 차례ì—� ê±¸ì³ ë§¤ë„: 31,207주는 가중í‰ê·� $55.2312 (범위 $55.00-$55.99), 3,593주는 가중í‰ê·� $56.1995 (범위 $56.00-$56.33)ì—� 매ë„.
  • 순주ì‹� 보유 현황: 행사 í›� 실제 보유 ì£¼ì‹ ìˆ˜ê°€ ì¼ì‹œì ìœ¼ë¡� 196,628주로 ì¦ê°€í–ˆìœ¼ë‚� ë§¤ë„ í›� 161,828주로 ê°ì†Œí•˜ì—¬ 거래 ì � 보유량과 ë³€ë� ì—†ìŒ.

해당 ë³´ê³ ëŠ� CEOì� ì¼ìƒì ì¸ 유ë™ì„� 관리임ì� 나타내며, 회사 현금 í름ì—는 ì˜í–¥ì� 없습니다. 거래가 사전ì—� 계íšë˜ì—ˆê³� ì „ì²´ 소유 ì§€ë¶„ì´ ë³€í•˜ì§€ 않아 시장ì—� 미치ëŠ� ì˜í–¥ì€ 제한ì ì¼ 것으ë¡� 보입니다.

Disc Medicine, Inc. (IRON) � Déclaration Formulaire 4 d'initié déposée le 11/07/2025

Le PDG et administrateur John D. Quisel a déclaré l'exercice d'une option et deux ventes sur le marché libre effectuées le 09/07/2025 dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 13/02/2025.

  • Exercice d'option (Code M) : 34 800 actions exercées à 9,86 $ par action, issues d'une attribution d'options du 1er septembre 2021 qui se dénoue en 48 versements mensuels égaux.
  • Ventes (Code S) : L'intégralité des 34 800 actions exercées a été vendue le même jour en deux tranches : 31 207 actions à un prix moyen pondéré de 55,2312 $ (fourchette 55,00-55,99 $) et 3 593 actions à un prix moyen pondéré de 56,1995 $ (fourchette 56,00-56,33 $).
  • Position nette en actions : La propriété bénéficiaire a brièvement augmenté à 196 628 actions après l'exercice, mais est retombée à 161 828 actions après les ventes, sans changement net par rapport à la participation avant la transaction.

La déclaration indique une gestion de liquidité de routine par le PDG ; aucun flux de trésorerie de l'entreprise n'est affecté. Étant donné que les transactions étaient planifiées à l'avance et que le niveau global de propriété reste inchangé, l'impact sur le marché est probablement limité.

Disc Medicine, Inc. (IRON) � Form 4 Insider-Transaktion eingereicht am 11.07.2025

CEO und Direktor John D. Quisel meldete die Ausübung einer Option und zwei Verkäufe am offenen Markt, die am 09.07.2025 im Rahmen eines am 13.02.2025 eingeführten Rule 10b5-1-Handelsplans durchgeführt wurden.

  • Optionsausübung (Code M): 34.800 Aktien zu je 9,86 $ ausgeübt, basierend auf einer Optionszuteilung vom 1. September 2021, die in 48 gleichen monatlichen Raten vestet.
  • Verkäufe (Code S): Die gesamten 34.800 ausgeübten Aktien wurden am selben Tag in zwei Tranchen verkauft: 31.207 Aktien zu einem gewichteten Durchschnittspreis von 55,2312 $ (Spanne 55,00-55,99 $) und 3.593 Aktien zu einem gewichteten Durchschnittspreis von 56,1995 $ (Spanne 56,00-56,33 $).
  • Nettoaktienposition: Das wirtschaftliche Eigentum stieg kurzzeitig auf 196.628 Aktien nach der Ausübung, fiel jedoch nach den Verkäufen auf 161.828 Aktien zurück, was zu keiner Nettoänderung gegenüber der Vortransaktion führte.

Die Meldung deutet auf routinemäßiges Liquiditätsmanagement des CEO hin; die Cashflows des Unternehmens bleiben unberührt. Da die Transaktionen vorab geplant waren und der Gesamtbesitz unverändert bleibt, ist die Marktwirkung wahrscheinlich begrenzt.

Positive
  • None.
Negative
  • CEO monetized 34,800 shares at ~$55â€�56, which some investors may interpret as reduced confidence despite the neutral net ownership position.

Insights

TL;DR: CEO exercised options then sold all 34,800 shares; ownership unchanged, routine 10b5-1 activity, limited signal.

The Form 4 shows John D. Quisel converting low-priced options ($9.86) into common stock and immediately liquidating the shares around $55-$56, capturing a sizable personal gain. Importantly, his final holding of 161,828 shares matches the pre-exercise level, so there is no dilution and no directional change in insider ownership. Because the trades were executed under a 10b5-1 plan adopted months earlier, they are less likely to reflect new information about Disc Medicine’s prospects. From an investor-sentiment perspective, the appearance of insider sales can be viewed cautiously, but the neutral net position and pre-planning largely offset this concern.

Disc Medicine, Inc. (IRON) � Transazione interna Form 4 presentata il 11/07/2025

Il CEO e Direttore John D. Quisel ha segnalato l'esercizio di un'opzione e due vendite sul mercato aperto eseguite il 09/07/2025 nell'ambito di un piano di trading Rule 10b5-1 adottato il 13/02/2025.

  • Esercizio opzione (Codice M): 34.800 azioni esercitate a 9,86 $ per azione, derivanti da un premio opzione del 1 settembre 2021 che si matura in 48 rate mensili uguali.
  • Vendite (Codice S): L'intero lotto di 34.800 azioni esercitate è stato venduto lo stesso giorno in due tranche: 31.207 azioni a un prezzo medio ponderato di 55,2312 $ (intervallo 55,00-55,99 $) e 3.593 azioni a un prezzo medio ponderato di 56,1995 $ (intervallo 56,00-56,33 $).
  • Posizione netta azionaria: La proprietà effettiva è salita brevemente a 196.628 azioni dopo l'esercizio, per poi scendere a 161.828 azioni dopo le vendite, senza variazioni nette rispetto alla quota precedente alla transazione.

La segnalazione indica una gestione di liquidità di routine da parte del CEO; non vi sono impatti sui flussi di cassa aziendali. Poiché le transazioni erano pianificate in anticipo e il livello complessivo di proprietà è rimasto invariato, l'impatto sul mercato è probabilmente limitato.

Disc Medicine, Inc. (IRON) � Transacción interna Formulario 4 presentada el 11/07/2025

El Director Ejecutivo y Director John D. Quisel reportó el ejercicio de una opción y dos ventas en mercado abierto realizadas el 09/07/2025 bajo un plan de negociación Rule 10b5-1 adoptado el 13/02/2025.

  • Ejercicio de opción (Código M): 34.800 acciones ejercidas a $9.86 por acción, provenientes de una concesión de opción del 1 de septiembre de 2021 que se adquiere en 48 cuotas mensuales iguales.
  • Ventas (Código S): La totalidad de las 34.800 acciones ejercidas se vendieron el mismo día en dos tramos: 31.207 acciones a un precio promedio ponderado de $55.2312 (rango $55.00-$55.99) y 3.593 acciones a un precio promedio ponderado de $56.1995 (rango $56.00-$56.33).
  • Posición neta de acciones: La propiedad beneficiaria aumentó brevemente a 196.628 acciones tras el ejercicio, pero volvió a bajar a 161.828 acciones después de las ventas, sin cambios netos respecto a la participación previa a la transacción.

La presentación indica una gestión rutinaria de liquidez por parte del CEO; no se afectan los flujos de caja de la empresa. Dado que las transacciones fueron planificadas con anticipación y el nivel general de propiedad no cambió, el impacto en el mercado probablemente sea limitado.

Disc Medicine, Inc. (IRON) â€� 2025ë…� 7ì›� 11ì� 제출ë� Form 4 ë‚´ë¶€ìž� 거래 ë³´ê³ 

최고경ì˜ìž� ê²� ì´ì‚¬ John D. QuiselëŠ� 2025ë…� 7ì›� 9ì¼ì— 2025ë…� 2ì›� 13ì� 채íƒë� Rule 10b5-1 거래 계íšì—� ë”°ë¼ ì˜µì…˜ 행사 ë°� ë‘� ê±´ì˜ ê³µê°œì‹œìž¥ 매ë„ë¥� 보고했습니다.

  • 옵션 행사 (코드 M): 2021ë…� 9ì›� 1ì� ë¶€ì—¬ëœ ì˜µì…˜ì—서 매월 48íš� 균등 ë¶„í• ë¡� 권리가 부여ë˜ëŠ� 34,800주를 주당 $9.86ì—� 행사í•�.
  • ë§¤ë„ (코드 S): 행사í•� 34,800ì£� 전량ì� ë‹¹ì¼ ë‘� 차례ì—� ê±¸ì³ ë§¤ë„: 31,207주는 가중í‰ê·� $55.2312 (범위 $55.00-$55.99), 3,593주는 가중í‰ê·� $56.1995 (범위 $56.00-$56.33)ì—� 매ë„.
  • 순주ì‹� 보유 현황: 행사 í›� 실제 보유 ì£¼ì‹ ìˆ˜ê°€ ì¼ì‹œì ìœ¼ë¡� 196,628주로 ì¦ê°€í–ˆìœ¼ë‚� ë§¤ë„ í›� 161,828주로 ê°ì†Œí•˜ì—¬ 거래 ì � 보유량과 ë³€ë� ì—†ìŒ.

해당 ë³´ê³ ëŠ� CEOì� ì¼ìƒì ì¸ 유ë™ì„� 관리임ì� 나타내며, 회사 현금 í름ì—는 ì˜í–¥ì� 없습니다. 거래가 사전ì—� 계íšë˜ì—ˆê³� ì „ì²´ 소유 ì§€ë¶„ì´ ë³€í•˜ì§€ 않아 시장ì—� 미치ëŠ� ì˜í–¥ì€ 제한ì ì¼ 것으ë¡� 보입니다.

Disc Medicine, Inc. (IRON) � Déclaration Formulaire 4 d'initié déposée le 11/07/2025

Le PDG et administrateur John D. Quisel a déclaré l'exercice d'une option et deux ventes sur le marché libre effectuées le 09/07/2025 dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 13/02/2025.

  • Exercice d'option (Code M) : 34 800 actions exercées à 9,86 $ par action, issues d'une attribution d'options du 1er septembre 2021 qui se dénoue en 48 versements mensuels égaux.
  • Ventes (Code S) : L'intégralité des 34 800 actions exercées a été vendue le même jour en deux tranches : 31 207 actions à un prix moyen pondéré de 55,2312 $ (fourchette 55,00-55,99 $) et 3 593 actions à un prix moyen pondéré de 56,1995 $ (fourchette 56,00-56,33 $).
  • Position nette en actions : La propriété bénéficiaire a brièvement augmenté à 196 628 actions après l'exercice, mais est retombée à 161 828 actions après les ventes, sans changement net par rapport à la participation avant la transaction.

La déclaration indique une gestion de liquidité de routine par le PDG ; aucun flux de trésorerie de l'entreprise n'est affecté. Étant donné que les transactions étaient planifiées à l'avance et que le niveau global de propriété reste inchangé, l'impact sur le marché est probablement limité.

Disc Medicine, Inc. (IRON) � Form 4 Insider-Transaktion eingereicht am 11.07.2025

CEO und Direktor John D. Quisel meldete die Ausübung einer Option und zwei Verkäufe am offenen Markt, die am 09.07.2025 im Rahmen eines am 13.02.2025 eingeführten Rule 10b5-1-Handelsplans durchgeführt wurden.

  • Optionsausübung (Code M): 34.800 Aktien zu je 9,86 $ ausgeübt, basierend auf einer Optionszuteilung vom 1. September 2021, die in 48 gleichen monatlichen Raten vestet.
  • Verkäufe (Code S): Die gesamten 34.800 ausgeübten Aktien wurden am selben Tag in zwei Tranchen verkauft: 31.207 Aktien zu einem gewichteten Durchschnittspreis von 55,2312 $ (Spanne 55,00-55,99 $) und 3.593 Aktien zu einem gewichteten Durchschnittspreis von 56,1995 $ (Spanne 56,00-56,33 $).
  • Nettoaktienposition: Das wirtschaftliche Eigentum stieg kurzzeitig auf 196.628 Aktien nach der Ausübung, fiel jedoch nach den Verkäufen auf 161.828 Aktien zurück, was zu keiner Nettoänderung gegenüber der Vortransaktion führte.

Die Meldung deutet auf routinemäßiges Liquiditätsmanagement des CEO hin; die Cashflows des Unternehmens bleiben unberührt. Da die Transaktionen vorab geplant waren und der Gesamtbesitz unverändert bleibt, ist die Marktwirkung wahrscheinlich begrenzt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Busch Kurt

(Last) (First) (Middle)
C/O MOBIX LABS, INC.
1 VENTURE, SUITE 220

(Street)
IRVINE CA 92618

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MOBIX LABS, INC [ MOBX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 07/09/2025 A 221,775(1) A $0.00 325,574 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option (Right to Buy) $4.18 (2) 08/10/2030 Class A Common Stock 20,000 20,000 D
Option (Right to Buy) $6.84 (2) 04/04/2032 Class A Common Stock 133,416 133,416 D
Explanation of Responses:
1. These Restricted Stock Units ("RSUs") were granted to the Reporting Person on July 9, 2025, whereas 90% of the award was fully vested upon grant and the remaining 10% will vest on October 1, 2025.
2. These options are fully vested and exercisable.
/s/ Terri Aprati, Attorney-in-Fact 07/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Disc Medicine (IRON) disclose in the July 11 2025 Form 4?

CEO John D. Quisel exercised 34,800 options at $9.86 and sold the same number of shares at ~$55�56 on 07/09/2025.

How many Disc Medicine shares does the CEO now own?

After the reported transactions, Quisel beneficially owns 161,828 common shares.

Were the insider sales pre-planned?

Yes. All transactions were executed under a Rule 10b5-1 trading plan adopted on February 13 2025.

What prices were the shares sold at?

Weighted-average prices were $55.2312 for 31,207 shares (range $55.00�$55.99) and $56.1995 for 3,593 shares (range $56.00�$56.33).

Did the CEO’s net ownership increase or decrease?

Neither. The exercise briefly increased holdings, but subsequent sales returned the stake to its prior level of 161,828 shares.
Mobix Labs Inc

NASDAQ:MOBX

MOBX Rankings

MOBX Latest News

MOBX Latest SEC Filings

MOBX Stock Data

42.70M
32.63M
31.53%
24.08%
3.14%
Semiconductors
Semiconductors & Related Devices
United States
IRVINE